DaVita Inc. (DVA) is a leading provider of dialysis services in the United States, serving more than 200,000 patients in over 2,700 outpatient dialysis centers nationwide. DaVita operates medical groups and affiliated physicians providing specialty services including nephrology, cardiology, and internal medicine.
Founded in 1994, DaVita, originally known as Total Renal Care Holdings, has its headquarters in Denver, Colorado. The name DaVita is derived from an Italian phrase, "dare vita," which translates to "giving life," reflecting the company's commitment to providing life-extending dialysis treatment to individuals with chronic kidney disease.
DaVita's primary operating division, DaVita Kidney Care, focuses on treating patients with end stage renal disease (ESRD), a condition that eventually requires dialysis or a kidney transplant. The company's services include in-center hemodialysis, peritoneal dialysis, home hemodialysis, vascular access management, chronic kidney disease education, and renal diet assistance.
Beyond dialysis services, DaVita also runs a network of comprehensive care clinics through its DaVita Medical Group. These clinics offer primary care and specialist services, integrated care management for individuals with significant chronic conditions, as well as interventions designed to address the social determinants of health.
DaVita's commitment to patient care extends into research as well; the company frequently collaborates with pharmaceutical and biotech companies to study and develop new treatments for kidney disease.
Furthermore, DaVita is deeply committed to social responsibility. Through the DaVita Way of Giving, the company's teammates, patients and physicians have contributed over $17 million to local non-profit organizations. Its Village Service Days encourage teammates to volunteer for events that support local communities.
In the stock market, DaVita Inc. trades under the ticker symbol DVA on the New York Stock Exchange. Its financial performance and commitment to improving quality of life for dialysis patients have made it a key player in the healthcare sector.
Through its innovative initiatives and leading healthcare provisions, DaVita has demonstrated its dedication to 'giving life.' The company's efforts continue to establish it as a premier provider of kidney care and a significant contributor to advancements in the healthcare industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Argus has issued a report on NeoGenomics, Inc. (NEO), an oncology diagnostic testing and consultative services provider. The report was published on September 23, 2026. The current price of NEO stock is $19.56.
Fred Hutch Cancer Center has acquired a former DaVita office building in Federal Way for $18 million. This purchase adds nearly 188,000 square feet to Fred Hutch's growing real estate portfolio. The acquisition was reported by Shawna De La Rosa of the Puget Sound Business Journal.
GE HealthCare has announced the appointment of AT&T's outgoing chief financial officer, Pascal Desroches, to its board of directors, effective January 4, 2027. Desroches, who plans to retire from AT&T at the end of the year, brings extensive financial leadership experience from his roles at AT&T and WarnerMedia. His appointment comes as GE HealthCare considers divesting its patient care solutions business.
/DaVita%20Inc%20location-%20by%20sanfel%20via%20iStock.jpg)
DaVita (DVA) stock has underperformed the S&P 500 over the past three months, despite strong longer-term gains and positive analyst expectations for future earnings. The recent dip followed its Q2 results, where investors focused on a decline in revenue per treatment. However, analysts maintain a "Moderate Buy" rating with significant upside potential.
DaVita Inc. (DVA) has shown mixed performance compared to the S&P 500. While it has underperformed over the past three months, DaVita has significantly outperformed the index over the past year and year-to-date. Analysts generally hold a "Moderate Buy" rating for the stock, expecting strong bottom-line growth in the coming years.
DaVita Inc. (NYSE: DVA), a healthcare provider specializing in kidney dialysis, shows a potential upside of 19.58% according to analyst targets, with an average target price of $219.86. Despite mixed analyst sentiment and some cautionary technical indicators, its strong revenue growth, impressive EPS, and strategic positioning in value-based healthcare models suggest a compelling opportunity for long-term growth. The company's financial health is further supported by a forward P/E of 10.66 and over $1 billion in free cash flow.
This article identifies three non-AI stocks—DaVita Inc. (DVA), Franklin Resources Inc. (BEN), and Archer Daniels Midland Co. (ADM)—that have demonstrated strong performance in 2026, returning over 30% YTD. These companies operate in sectors like healthcare, asset management, and agriculture, showing resilience and growth independent of the AI boom. The article suggests they could serve as diversification plays for investors concerned about an AI bubble or looking to balance their portfolios.